Thank you, Mr. Chair.
Hi, Dr. Bengio. Thank you for joining us today. My questions will be for you.
Much of your work rightly focuses on the risks and safety challenges of superintelligent AI. In places like my community of Kitchener Centre, Canada's innovation capital, we're seeing specialty AI help support people with brain injuries, diagnose disease, assist in civic planning and streamline processes to drive real innovation, productivity and economic opportunity.
Can you please explain the difference between specialty AI in sectors like science and research, health care and industry, for example, and superintelligent AI, which the developers themselves admit they have no control over?